Is Cherry Eye Covered by Pet Insurance?
Breed-specific exclusions and waiting periods apply with some insurers.
What is cherry eye in dogs?
Cherry eye is a prolapse of the nictitating membrane gland – the tear-producing gland behind the third eyelid that generates around 50% of a dog’s tear film. When the connective tissue anchoring this gland weakens, the gland protrudes from beneath the third eyelid, creating a distinctive red or pink swelling at the inner corner of the eye.
The condition affects roughly 1 in 500 dogs each year in the UK, according to a 2022 VetCompass study analysing 905,553 dogs across UK veterinary practices [1].
Cherry eye is most common in young dogs – the average age at diagnosis is just 0.6 years, and dogs under one year face 10.8 times the risk compared with dogs aged two to four.
Cherry eye is a structural problem, not an infection. Eye drops and topical medications do not resolve it.
Surgical repositioning – typically using the pocket technique or tuck procedure – is the only effective long-term treatment.
Which breeds are most at risk of cherry eye?
Brachycephalic (flat-faced) breeds carry 6.9 times the risk of cherry eye compared with dogs that have a medium-length skull, according to the same VetCompass study [1]. English Bulldogs face the highest risk among popular breeds at 24.1 times that of crossbreeds, with Neapolitan Mastiffs at 34.3 times and Lhasa Apsos at 12.4 times.
Eye conditions feature heavily in a couple of breeds in particular. Read about the health conditions Cocker Spaniels are prone to and the eye and other conditions French Bulldogs are prone to.
Other breeds with elevated risk include French Bulldogs, Cocker Spaniels, Boston Terriers, Shih Tzus, Great Danes, Beagles, Pugs, and Pekingese.
Some designer crossbreeds also carry significant risk – Puggles (Pug x Beagle) face 9.5 times the risk and Jugs (Jack Russell x Pug) face 5.2 times the risk.
Cherry eye can occur in any breed, but genetic predisposition drives the vast majority of cases. If you own a high-risk breed, insuring from 8 weeks of age – before cherry eye develops – is the single most effective way to ensure coverage exists when treatment becomes necessary.
What are the symptoms of cherry eye?
Cherry eye presents as a red or pink, round, fleshy mass protruding from the inner corner of one or both eyes.
The swelling may be constant or intermittent, sometimes appearing and retracting before becoming permanently visible.
Secondary symptoms can include mild eye discharge, slight squinting, or pawing at the affected eye if irritation develops. Many dogs show no behavioural signs of discomfort – the prolapsed gland itself is typically painless unless secondary inflammation or infection sets in.
Cherry eye does not cause the redness, heavy discharge, or crusty eyes associated with conjunctivitis or bacterial infection.
If those symptoms accompany the swelling, secondary infection may have developed and requires immediate veterinary attention.
Does pet insurance cover cherry eye surgery?
Pet insurance covers cherry eye surgery under most accident and illness policies in the UK, provided the condition developed after the policy start date and outside the waiting period. Surgical repositioning is reimbursed against the annual benefit limit, minus the excess.
Coverage varies by policy type.
Lifetime cover reimburses cherry eye treatment across multiple policy years if recurrence occurs, resetting the annual limit upon renewal. Time-limited policies cover the condition for 12 months from the first claim date.
Maximum benefit policies cap total reimbursement per condition regardless of duration.
Accident-only policies do not cover cherry eye unless the prolapse results directly from trauma (such as a dog fight or collision). Cherry eye caused by genetic predisposition – which accounts for the vast majority of cases – is classified as an illness, not an accident.
Why are cherry eye claims declined?
Cherry eye claims are declined most commonly because of pre-existing condition clauses.
If your dog showed symptoms before the policy start date – even if you did not seek veterinary diagnosis – the insurer can classify the condition as pre-existing and permanently exclude it from cover.
Hereditary condition exclusions also apply with some insurers, particularly for breeds with documented genetic predisposition. A policy may exclude “hereditary eye conditions” as a blanket category, which captures cherry eye even if your individual dog has no family history of the condition.
Waiting period breaches are another common cause.
Most policies apply a 14-day waiting period for illness claims from the policy start date. If cherry eye symptoms appear within those 14 days, the claim will not be paid.
What is the bilateral condition trap?
The bilateral condition trap is the coverage complication created by bilateral cherry eye – where both eyes are affected – that catches many owners by surprise.
Some insurers treat bilateral conditions as linked, meaning if one eye developed cherry eye before the policy started, the second eye is also excluded – even if it developed symptoms months or years later.
This bilateral exclusion exists because insurers consider a condition affecting both sides of the body to be the same underlying condition. If your dog’s left eye had cherry eye before you took out insurance and the right eye develops it after, the insurer may decline the claim for the right eye on pre-existing bilateral grounds.
Before claiming for bilateral cherry eye, contact your insurer and ask explicitly how they classify bilateral conditions.
Request their answer in writing so you have confirmation if a dispute arises. This step alone can prevent unexpected claim rejections.
How much does cherry eye surgery cost in the UK?
Cherry eye surgical repositioning typically costs between £300 and £1,500 per eye in the UK, depending on your veterinary practice, location, and whether the procedure is routine or emergency.
Not-for-profit clinics such as Animal Trust quote around £389 per eye, whilst private referral practices often charge £800–1,500 per eye.
Bilateral surgery (both eyes in one procedure) increases the total cost due to extended surgical and anaesthetic time. Owners report paying between £800 and £2,500 for bilateral repositioning at private practices.
Pre-operative consultations, eye examinations, and post-operative medications (anti-inflammatory drops, antibiotics) add further to the bill.
If complications develop – such as corneal ulcers from delayed treatment or surgical recurrence requiring a second procedure – costs can escalate significantly. Early treatment is more cost-effective than managing complications later.
How long is the waiting period for cherry eye claims?
Most UK pet insurance policies apply a 14-day waiting period for illness claims, including cherry eye.
Claims for symptoms presenting within 14 calendar days of the policy start date will typically be declined. Accident-related eye injuries may have shorter or zero waiting periods, but cherry eye caused by genetic predisposition is classified as illness.
Some insurers offer waiting period waivers or reductions for an additional premium at quote stage.
If you are insuring a high-risk breed puppy, ask about this option – the cost difference is usually small compared with the potential claim value of cherry eye surgery.
What happens if cherry eye is left untreated?
Untreated cherry eye leads to chronic drying of the eye surface, as the prolapsed gland cannot produce tear film effectively. This causes secondary conjunctivitis, excessive mucus discharge, and increased risk of corneal ulcers – all of which are painful and require additional treatment.
What starts as a £300–£800 repositioning surgery can escalate to £1,500 or more if corneal damage develops.
From both a welfare and financial perspective, early surgical intervention produces better outcomes than waiting to see if the gland retracts on its own.
Some owners report that mild cherry eye resolved with lubricating drops after teething, but relying on spontaneous resolution is risky. The gland produces around half of your dog’s tear film – leaving it exposed and non-functional invites long-term eye health problems.
Can cherry eye be prevented?
Cherry eye cannot be prevented in genetically predisposed breeds because the condition stems from inherited weakness in the connective tissue anchoring the third eyelid gland – no diet, supplement, or eye care routine alters this genetic trait.
The condition stems from inherited weakness in the connective tissue anchoring the third eyelid gland – no diet, supplement, or eye care routine alters this genetic trait.
Early detection is the best strategy. Check the inner corners of both eyes weekly during grooming, particularly if your dog is a high-risk breed.
Regular eye examinations during puppy vaccination appointments help catch cherry eye before secondary complications develop.
Insuring your puppy from 8 weeks of age – before cherry eye has a chance to develop – remains the most effective financial protection. Pre-existing condition exclusions are permanent with most insurers, so the timing of your policy start date matters enormously for breeds prone to early-onset conditions like cherry eye.
What should you check in your policy before claiming?
Before submitting a cherry eye claim, verify five things in your policy documents: whether cherry eye or “hereditary eye conditions” are listed as permanent exclusions; whether you are still within the waiting period; how your insurer classifies bilateral conditions; your remaining annual benefit limit; and whether surgical repositioning is covered under your policy tier.
Contact your insurer before booking surgery and request pre-authorisation in writing.
Provide the veterinary estimate, your dog’s breed, age, and policy number. Pre-authorisation does not guarantee payment, but it surfaces any exclusions or waiting period issues before you commit to surgery costs.
If your claim is declined, request written explanation of the reason – pre-existing, hereditary exclusion, waiting period breach, bilateral clause, or annual limit exceeded.
Use that explanation to decide whether to appeal directly with the insurer or escalate to the Financial Ombudsman Service.
References
[1] O’Neill, D. G., Yin, Y., Tetas Pont, R., Brodbelt, D.
C., Church, D. B., Pegram, C., & Mustikka, M. (2022). “Breed and conformational predispositions for prolapsed nictitating membrane gland (PNMG) in dogs in the UK: A VetCompass study.” PLOS ONE, 17(1), e0260538.
